JSAM
NRIX icon

J. Safra Asset Management’s Nurix Therapeutics NRIX Stock Holding History

J. Safra Asset Management’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-158
Closed -$1.46K – 656
2025
Q3 		$1.46K Hold
158
– – ﹤0.01% 441
2025
Q2 		$1.8K Buy
158
+61
+63% +$659 ﹤0.01% 353
2025
Q1 		$1.15K Buy
97
+82
+547% +$1.37K ﹤0.01% 333
2024
Q4 		$280 Buy
+15
New +$344 ﹤0.01% 335

Other funds holding NRIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

J. Safra Asset Management's NRIX Position: Q4 2025 in Review

J. Safra Asset Management sold out of Nurix Therapeutics (NRIX) in Q4 2025, closing a stake of 158 shares — an estimated $1.46K sold.

J. Safra Asset Management first reported a position in NRIX in Q4 2024 and held it in 4 quarters. The position peaked at $1.8K in Q2 2025. 182 funds tracked by Wall St. Rank hold NRIX as of Q4 2025.

  • J. Safra Asset Management reported no remaining Nurix Therapeutics position as of Q4 2025 after selling out during the quarter.
  • J. Safra Asset Management sold 158 Nurix Therapeutics shares in Q4 2025, an estimated $1.46K.
  • J. Safra Asset Management first reported a position in Nurix Therapeutics in Q4 2024 and held it in 4 quarters.
  • J. Safra Asset Management's Nurix Therapeutics position peaked at $1.8K in Q2 2025.
  • 182 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q4 2025.

Based on J. Safra Asset Management's 13F filing for Q4 2025, filed 11 Feb 2026.